Eli Lilly (LLY)

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of $1.12 trillion.

Shares recently traded at $1,280 each, so a split wouldn't be surprising.

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Can anyone challenge Eli Lilly in the weight loss space?

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.

These two stocks both have market caps of more than $1 trillion, but Eli Lilly's valuation is supported by strong financials.

Biotech extends runway to 2028 with $100M financing and Eli Lilly deal.

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion obesity market.

Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana

Investors can reap big rewards over the long term by betting on growth in their younger years.

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket

The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

They are fairly risky, but their potential upside is massive.

The company's peers in the pharmaceutical industry should be worried.

They are way more than just GLP-1 stocks.

The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.